Idenix regains drug rights from partner Novartis
(Reuters) - Idenix Pharmaceuticals Inc said it regained the worldwide rights to develop, market and license its drug candidates from Swiss partner and stakeholder Novartis. Idenix, whose experimental treatments for hepatitis C have led to extensive investor interest, said Novartis's rights to license Idenix's current and future development-stage drugs for any disease has been terminated. In exchange, Idenix will pay Novartis a royalty based on the worldwide sales of Idenix's future hepatitis C drugs, unless they are used in combination with Novartis' drugs. ...
Source: news.yahoo.com
No comments:
Post a Comment